The pipeline of Zealand Pharma AS of Denmark is advancing strongly towards a catalyst-filled 2020 that the biotech hopes bring it four US drug approvals and lead to subsequent commercial launches starting from 2021, its CEO told Scrip in an interview.
Until only recently largely known for developing the Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?